--- title: "U.S. Stock Market Midday Update: YD Bio Soars 109% in 10 Days Without Any Good News? Speculative Trading May Carry Adjustment Risks" type: "News" locale: "en" url: "https://longbridge.com/en/news/296526936.md" description: "YD Bio rose 10.52%; Moderna fell 22.34%, with a transaction volume reaching USD 11.2 billion; AbbVie fell 0.70%, with a transaction volume reaching USD 769 million; Amgen fell 1.97%, with a transaction volume reaching USD 529 million; Gilead Sciences fell 1.60%, with a market value of USD 180.1 billion" datetime: "2026-08-20T18:48:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296526936.md) - [en](https://longbridge.com/en/news/296526936.md) - [zh-HK](https://longbridge.com/zh-HK/news/296526936.md) generator: "portal-rs" --- # U.S. Stock Market Midday Update: YD Bio Soars 109% in 10 Days Without Any Good News? Speculative Trading May Carry Adjustment Risks **U.S. Stock Market Midday Update** YD Bio, up 10.52%, with a 10-day increase of 108.98%, recently has no significant news. Trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Moderna down 22.34%. Based on recent key news: 1. On August 19, Moderna's mRNA cancer vaccine, developed in collaboration with Merck, achieved positive results in Phase III clinical trials, leading to a significant increase in stock price. The vaccine significantly reduced the risk of melanoma recurrence, pushing Moderna's stock price up 107% in pre-market trading. Source: Guandian.com 2. On August 20, market sentiment cooled, and investors began to take profits, leading to a decline in Moderna's stock price. UBS data shows that after a record sell-off on Wednesday, the stock price fell back. Source: UBS 3. On August 20, analysts pointed out that Moderna's valuation is too high, and the market's expectations for the cancer vaccine are overly optimistic, leading to a stock price adjustment. RBC Capital raised the target price to $130 but maintained a Sector Perform rating. Source: RBC Capital. The volatility in the biotechnology sector has intensified, and investors need to be cautious. AbbVie down 0.70%, with increased trading volume. Based on recent key news: 1. On August 18, Haisco and AbbVie reached a cooperation agreement, granting AbbVie exclusive rights to develop, produce, and commercialize HSK51155 globally, with a potential total deal value exceeding $700 million. This collaboration may have a positive impact on AbbVie's long-term growth. 2. On August 19, AbbVie executives exercised stock options and sold shares, which may raise market concerns about internal confidence in the company, leading to stock price volatility. 3. On August 20, analysts maintained AbbVie's rating at "Outperform," but it was not included in the top recommended stocks list, which may affect investor confidence. The pharmaceutical industry is facing intensified competition and high R&D costs. Amgen down 1.97%, with increased trading volume. Based on recent key news: 1. On August 18, Amgen announced the termination of its research collaboration agreement with TScan Therapeutics. This move may raise market concerns about the execution risks of its R&D pipeline, leading to a decline in stock price. 2. On August 19, market analysts maintained a "Hold" rating on Amgen and did not include it in the recommended buy list. Analysts are cautious about its future performance, affecting investor confidence. 3. On August 20, Piper Sandler raised Amgen's target price from $427 to $457. Despite the target price increase, the market remains cautious about its short-term performance. The biopharmaceutical industry faces policy and R&D risks **Stocks Ranked Among the Top by Market Capitalization in the Industry** Gilead Sciences fell by 1.60%. Based on recent key news: 1. On August 17, Gilead Sciences' Chief Communications and Corporate Affairs Officer Johanna Mercier exercised stock options to purchase 25,000 shares and sold 28,000 shares on the same day at a price of approximately $137.37 to $138.04 per share. This insider trading activity may have negatively impacted market sentiment. 2. On August 18, Evan Seigerman, an analyst at BMO Capital, reiterated a buy rating on Gilead Sciences with a target price of $174. However, Barclays maintained a hold rating on the company on August 13, which may lead to differing views on its prospects in the market. 3. On August 20, Gilead Sciences' cell therapy business revenue decreased by 12% year-on-year, primarily due to intensified market competition, while joint development with partner Arcus Biosciences faced obstacles, posing a threat to its tumor diversification plans. Macroeconomic pressures are affecting the biotechnology industry ### Related Stocks - [YDES.US](https://longbridge.com/en/quote/YDES.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) ## Related News & Research - [Moderna stock soars on cancer vaccine success](https://longbridge.com/en/news/296405393.md) - [MEXC Lists Ondo Tokenized Stock Moderna (MRNAON), Expanding Access to U.S. Biotech Exposure](https://longbridge.com/en/news/296603043.md) - [If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now](https://longbridge.com/en/news/296641626.md) - [Moderna’s 177% Surge Has Investors Asking What Comes Next](https://longbridge.com/en/news/296610623.md) - [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**